SG3 Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-2,500
Closed -$339K 1390
2021
Q1
$339K Buy
+2,500
New +$374K 0.01% 868
2020
Q3
Sell
-205,700
Closed -$23M 1091
2020
Q2
$23M Buy
205,700
+203,700
+10,185% +$20.1M 1.59% 8
2020
Q1
$155K Buy
+2,000
New +$177K 0.02% 273

Other funds holding XBI

SG3 Management's XBI Position: Q3 2020 in Review

SG3 Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2020, closing a stake of 3,000 shares — an estimated $336K sold.

SG3 Management first reported a position in XBI in Q2 2020 and held it in 1 quarter. The position peaked at $336K in Q2 2020. 554 funds tracked by Wall St. Rank hold XBI as of Q3 2020.

  • SG3 Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2020 after selling out during the quarter.
  • SG3 Management sold 3,000 State Street SPDR S&P Biotech ETF shares in Q3 2020, an estimated $336K.
  • SG3 Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 1 quarter.
  • SG3 Management's State Street SPDR S&P Biotech ETF position peaked at $336K in Q2 2020.
  • 554 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2020.

Based on SG3 Management's 13F filing for Q3 2020, filed 13 Nov 2020.